
Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.

Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.

Join global expert Dr. Michael Wechsler as he discusses type 2 inflammation in COPD.

Join global expert Professor Ian Pavord as he discusses the heterogeneity of underlying inflammation in patients with COPD.

Dr. Casale discusses the critical role of barrier disruption in atopic dermatitis

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.